Profile of temsirolimus in the treatment of advanced renal cell carcinoma
Michael Staehler, Nicolas Haseke, Wael Khoder, Christian G Stief
Department of Urology, University of Munich, Klinikum Grosshadern, Germany
Abstract: Temsirolimus is a potent inhibtor of the mammalian target of rapamycin (mTOR). In various clinical trial temsirolimus has shown an overall survival benefit for patients with metastatic renal cell carcinoma (mRCC). Thus it is approved for first-line therapy in high-risk mRCC patients. We discuss the indication, side effects and clinical implications of temsirolimus treatment.
Keywords: renal cell cancer, non-clear cell renal cancer, temsirolimus, first-line therapy, overall survival, nephrectomy
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF]